About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Bipolar Disorder Clinical Trials in Philadelphia | 47 Studies | Clareo Health

Clinical Trials Bipolar DisorderPhiladelphia

Bipolar Disorder Clinical Trials in Philadelphia

Find 47 clinical trials for bipolar disorder near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Bipolar Disorder trials nationwide All trials in Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 21-40 of 47 trials

COMPLETEDPHASE4< 1 mile

Comparative Effectiveness Study for Bipolar Disorder

NCT01331304

The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.

Bipolar Disorder

Massachusetts General Hospital482 participantsStarted Sep 2010

Birmingham, Alabama, United States • Stanford, California, United States • Boston, Massachusetts, United States +8 more locations

COMPLETEDPHASE4< 1 mile

Bipolar Study in Adults at Least 18 Years of Age

NCT00067938

Bipolar study of tolerability, clinical response and patient satisfaction

Bipolar Disorder

GlaxoSmithKline1,200 participantsStarted Aug 2003

Albertville, Alabama, United States • Anniston, Alabama, United States • Birmingham, Alabama, United States +305 more locations

Bipolar Disorder Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

COMPLETED< 1 mile

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

NCT01149551

The purpose of this study is to detect genetic associations for the development of schizophrenia (SZ) and bipolar illness (BP) by comparing Veterans with these diseases to "psychiatrically healthy" Veterans from Veterans Health Administration medical centers. In addition, the genetic basis for functional capacity and disability in Veterans affected with SZ and BP will be assessed, as will genetic predictors of suicidality and tardive dyskinesia. Finally, we will also establish a repository which allows for future genomic studies related to SZ, BP, and related disorders or sequelae.

SchizophreniaBipolar Disorder

US Department of Veterans Affairs9,356 participantsStarted Feb 2011

Birmingham, Alabama, United States • Tuscaloosa, Alabama, United States • No. Little Rock, Arkansas, United States +22 more locations

COMPLETEDNA< 1 mile

Bipolar Disorder Research Study for Ages 12 and Older

NCT00211263

The Bipolar Disorder Center for Pennsylvanians aims to reduce significant differences in treatment results among Pennsylvanians with bipolar disorder, especially among youth, the elderly, rural residents, and African Americans who are less likely to receive adequate treatment, less likely to remain in treatment once identified, and less likely to have positive results if they remain in treatment. Half of the subjects receive either Guideline Intervention (GI) or Enhanced Clinical Intervention (ECI). ECI is a combination of information and support, such as education about bipolar disorder, the medications used to treat it, information about sleep practices and habits that affect quality of sleep, review of symptoms, medication side effects, and coping with side effects. It is predicted that Enhanced Clinical Intervention will be more effective in reducing the differences in results between those most at risk compared to mid-life Caucasians. The treatment study occurs at three sites across Pennsylvania and has emphasized the recruitment of African Americans, youth (ages 12 through 18), and adults over age 65.

Bipolar Disorder

Kupfer, David J., M.D.750 participantsStarted Nov 2003

DuBois, Pennsylvania, United States • Philadelphia, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States

COMPLETEDPHASE3< 1 mile

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

NCT00868699

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

Bipolar Depression

Sumitomo Pharma America, Inc.505 participantsStarted Apr 2009

Escondido, California, United States • Garden Grove, California, United States • Oceanside, California, United States +52 more locations

COMPLETEDPHASE3< 1 mile

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

NCT00090311

The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania.

Bipolar Disorder

AstraZeneca220 participantsStarted Jul 2004

Scottsdale, Arizona, United States • Riverside, California, United States • Sacramento, California, United States +29 more locations

COMPLETEDPHASE3< 1 mile

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

NCT00083954

The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.

Bipolar Disorder

AstraZeneca530 participantsStarted Jun 2004

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Cerritos, California, United States +33 more locations

COMPLETEDPHASE3< 1 mile

Seroquel in Bipolar Depression Versus SSRI

NCT00119652

The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.

Bipolar DisorderBipolar DepressionDepression

AstraZeneca676 participantsStarted May 2005

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • National City, California, United States +52 more locations

COMPLETEDPHASE312 miles

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

NCT01358357

This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and /or psychotic features.

Bipolar I Disorder

Sumitomo Pharma America, Inc.965 participantsStarted Jun 2011

Dothan, Alabama, United States • Glendale, California, United States • Los Angeles, California, United States +102 more locations

COMPLETEDPHASE312 miles

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

NCT01575561

This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of subjects with bipolar I disorder, who have either completed the core study D1050296 or experienced a protocol defined recurrence of a mood event in the double-blind phase of the core study D1050296

Bipolar I Disorder

Sumitomo Pharma America, Inc.377 participantsStarted Jun 2012

Dothan, Alabama, United States • Glendale, California, United States • Los Angeles, California, United States +68 more locations

COMPLETEDPHASE314 miles

Depression And Bipolar Disorder

NCT00274677

This study is an 8-week evaluation of an investigational drug for treating depression in bipolar patients. Depressed patients will be given either an investigational drug or placebo and receive psychiatric assessments of their depression at weekly visits. Study drug and all study-related visits are provided at no cost to the patient. The patient agrees to meet with study research staff for roughly 11 clinic visits.

Bipolar Disorder

GlaxoSmithKline221 participantsStarted Nov 2003

Burbank, California, United States • Loma Linda, California, United States • San Diego, California, United States +16 more locations

COMPLETEDPHASE317 miles

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

NCT01059539

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.

Bipolar I Disorder

Forest Laboratories403 participantsStarted Feb 2010

Springdale, Arkansas, United States • Carson, California, United States • Cerritos, California, United States +32 more locations

COMPLETEDPHASE317 miles

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

NCT02670551

This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Bipolar DisorderDepression

Forest Laboratories488 participantsStarted Mar 2016

Little Rock, Arkansas, United States • Costa Mesa, California, United States • Escondido, California, United States +71 more locations

COMPLETEDPHASE338 miles

Bipolar Disorder Study for Men and Women

NCT00056277

A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder

Bipolar Disorder

GlaxoSmithKline150 participantsStarted Feb 2003

Beverly Hills, California, United States • La Jolla, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPHASE363 miles

Pediatric Open-Label Extension Study

NCT01914393

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

SchizophreniaAutismBipolar Depression

Sumitomo Pharma America, Inc.702 participantsStarted Sep 2013

Dothan, Alabama, United States • Downey, California, United States • San Francisco, California, United States +85 more locations

COMPLETEDPHASE481 miles

Optimizing Electroconvulsive Therapy for Depression

NCT00045916

This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.

DepressionDepressive DisorderBipolar Disorder

New York State Psychiatric Institute340 participantsStarted Feb 2001

St Louis, Missouri, United States • New York, New York, United States • Winston-Salem, North Carolina, United States +1 more locations

COMPLETEDPHASE494 miles

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582

The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.

SchizophreniaBipolar DisorderAutistic Disorder+1 more

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.244 participantsStarted Oct 2009

San Francisco, California, United States • Aurora, Colorado, United States • Altamonte Springs, Florida, United States +25 more locations

COMPLETEDPHASE3104 miles

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01396291

This study is being done to evaluate the efficacy and safety of asenapine as compared to placebo in preventing the recurrence of mood episodes after stabilization of an acute/manic mixed episode in participants with Bipolar 1 Disorder. After a Screening Period, each participant will receive open-label asenapine and matching placebo for 12 to 16 weeks. Participants who meet stabilization criteria may then be randomized into one of the two study arms (asenapine or matching placebo) to receive double-blind treatment for up to an additional 26-weeks.

Bipolar 1 Disorder

Forest Laboratories561 participantsStarted Dec 2011

Anaheim, California, United States • Chino, California, United States • Escondido, California, United States +77 more locations

COMPLETEDPHASE2269 miles

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

NCT00490542

Mixed states in bipolar disorder have long been recognized. Over a century ago, it was argued that mixed states were the most common episodes in manic-depressive illness. A mixed state is defined as a person who is experiencing symptoms of both depression and mania. Currently, a person must have depression plus 3 or more manic symptoms for the episode to be diagnosed mixed. Using this narrow view, less than 10% of episodes in patients with bipolar disorder would meet criteria for a mixed episode. A broader view requires that the person have at least 2 manic symptoms. Using this broader view, data suggest that about 50% of episodes in bipolar disorder would be diagnosable as mixed states. Studies suggest that the majority of persons with a depressive mixed state have bipolar disorder type II. Many people who have a mixed state will also have major depression. Even with such high potential rates of mixed episodes in both bipolar disorder and major depression, there have been few studies addressing the issue. The purpose of this study is to look at how effective Geodon is in treating the depressive mixed state in people with bipolar or major depression. This will be the first clinical trial that is both double-blind and randomized.

Bipolar DisorderBipolar DepressionDepression

Tufts Medical Center73 participantsStarted Dec 2006

Chicago, Illinois, United States • Boston, Massachusetts, United States • Cambridge, Massachusetts, United States +1 more locations

COMPLETEDPHASE4271 miles

Memantine and Cognitive Dysfunction in Bipolar Disorder

NCT00586066

The purpose of this study is to see whether memantine improves memory function in participants with bipolar disorder who have minimal symptoms. Secondary analyses will test the role of memantine in improving residual mood symptoms (depression and mania) in participants with bipolar disorder. We hypothesize that in participants with bipolar disorder who have minimal symptoms memantine will be effective in improving cognitive functions, as measured by the difference in neuropsychological test scores at the beginning and at the end of the trial.

Bipolar Disorder

Massachusetts General Hospital72 participantsStarted Nov 2005

Los Angeles, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States

PreviousPage 2 of 3Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia